Achondroplasia

Ryan W Y Lee MD

Developmental Malformations

Updated 05.20.2024
Released 03.03.2011
Expires For CME 05.20.2027

Achondroplasia

Author: Ryan W Y Lee MD

See Contributor Disclosures

Editor: Ann Tilton MD

Achondroplasia

In This Article

Quick Link

Introduction

Overview

Achondroplasia is an autosomal dominant disorder of bone formation caused by mutations in fibroblast growth factor receptor type 3 (FGFR3). Characteristic features include disproportionate short stature, an enlarged head with frontal bossing, midface hypoplasia, rhizomelic shortening of the limbs, and trident-shaped hands. Targeted therapeutics in the form of tyrosine kinase inhibitors show promise in animal studies for the treatment of FGFR3-related skeletal dysplasias. In this article, the author discusses the clinical neurologic aspects and molecular mechanisms involved in achondroplasia.

Key points

	• Achondroplasia is a disorder of bone formation primarily affecting the long bones of the extremities and the base of the skull, resulting in characteristic features of short extremities, a large head, and trident-shaped hands.
	• Achondroplasia is an autosomal dominant disorder caused by mutations in fibroblast growth factor receptor type 3 (FGFR3), with about 80% of parents unaffected.
	• Features of achondroplasia are so distinctive that physical exam and radiographic features are often sufficient to make a diagnosis.
	• Concerning neurologic signs include hydrocephalus and spinal stenosis secondary to either small craniocervical junction or advanced lumbar lordosis.
	• Management involves identification and treatment of comorbidities that cause functional and social impairment. Experimental targeted therapeutic strategies include reduction in FGFR3 signaling through tyrosine kinase inhibitors, neutralizing antibodies, soluble FGFR-3, and statins.

Historical note and terminology

The term “achondroplasia” was proposed by Jules Parrott in 1878 to describe a condition of children and adults with disproportionate short stature (93). In 1900, Pierre Marie further investigated the physical and intellectual features of the patient population and introduced clinical terminology such as “trident-shaped hands” (23). Achondroplasia is a disorder of bone formation, primarily affecting the long bones of the extremities and the base of the skull, resulting in characteristic features of short extremities, a large head, and trident-shaped hands (23). Achondroplasia literally translates as “without cartilage formation,” but this is a misnomer because the problem does not involve formation of cartilage, but rather lies in the conversion of cartilage to bone (ossification). The clinical spectrum of disease ranges from hypochondroplasia (mild) to achondroplasia (severe).

Although Parrott and Marie are credited as the first modern scientists to clinically describe achondroplasia, archeological evidence in artisan and fossil records substantiate recognition of the condition in ancient Egyptian, Greek, and Roman civilizations (63). Additionally, a Korean study reported dwarfism-related skeletal dysplasias from the Joseon Dynasty (142). Egypt was the most important source of information about achondroplasia in the Old World. Individuals with achondroplasia, or “dwarfs” as termed by archeological scholars, were assimilated into the daily life of ancient Egypt, and their disorder was not recognized as a physical disability. Artisan sculptures, paintings, and skeletal remains dating as early as 4500 BCE depict dwarfs employed as animal tenders, personal attendants, entertainers, and jewelers (25). Several dwarfs attained high-ranking positions in the Old Kingdom (2700 to 2190 BCE) society and, as a result, were buried in extravagant tombs in royal cemeteries close to the Egyptian pyramids (24; 28; 137). There were at least two dwarf gods, Ptah and Bes, which represented regeneration and protection during childbirth, respectively (64). Furthermore, Egyptian moral teachings and wisdom writings commanded respect for dwarfs and other individuals with disabilities (63). Ancient Egyptian representations of achondroplasia continue to receive appreciation in contemporary art galleries such as the Walters Art Museum in Baltimore, Maryland (65). Techniques for appropriate methodology for identifying achondroplasia from the cranial skeleton alone have been proposed by archaeologists studying historic remains (38).

Clinical manifestations

Presentation and course

The physical abnormalities of achondroplasia include disproportionate short stature, an enlarged head with frontal bossing, midface hypoplasia, rhizomelic (proximal) shortening of the limbs with redundant skin folds, limited elbow extension, thoracolumbar gibbus in infancy, exaggerated lumbar lordosis, genu varum (bow legs), trident-shaped hands (short fingers with divergent ring and middle fingers), and a protuberant abdomen (26). Abnormal bone in people with achondroplasia is subject to distortion, and the result is that bone impinges on nervous tissue, most commonly at the foramen magnum, spinal canal, and nerve root outlet foramen. Awareness of the range of these complications allows early and more effective intervention so as to ameliorate the nature and severity of the long-term effects of the neurologic complications in patients with achondroplasia (09).

There are numerous neurologic manifestations of achondroplasia (35; 94; 09). Neonatal and childhood neurologic features include hydrocephalus, small craniocervical junction, truncal hypotonia, and articulation problems. For the newborn, hydrocephalus may be due to a small craniocervical junction leading to foramen magnum or aqueduct stenosis. As growth continues, hydrocephalus is often the communicating type resulting from increased intracranial venous pressure (30; 13). In rare cases, hydrocephalus may be caused by a concomitant Chiari II malformation (04). Intelligence is typically normal, unless hydrocephalus or other central nervous system complications occur (37). Developmental delays are often the consequence of transient neuromuscular hypotonia, chronic upper airway obstruction, middle ear dysfunction, craniocervical junction stenosis, lordosis or kyphosis, and bowing of the legs (130; 51). Thoracolumbar kyphosis is common in children and typically improves without treatment as they begin to ambulate; however, when individuals enter adulthood, lumbar lordosis and bowing of the legs become a significant problem.

Achondroplasia carries with it many associated disorders, including obstructive sleep apnea, recurrent otitis media, obesity, and joint laxity (48; 22). Mid-face hypoplasia leads to narrow upper airways and shortened eustachian tubes, predisposing patients to obstructive sleep apnea and recurrent otitis media, respectively (48). Conductive hearing loss secondary to recurrent otitis is seen in up to 40% of patients, and hearing screening should be performed when language delay is present (50). An underdeveloped chest cavity can lead to restrictive lung disease, especially in early childhood. Ligamentous laxity in the lower extremities, defined as the clinician’s ability to passively oppose the lateral borders of the feet when brought together in the midline, above the level of the pelvis in a seated position, was found in about 90% of individuals with achondroplasia. This sign has been termed “Scott sign” after Dr. Charles Scott, former Chairman of the Medical Advisory Board to the Little People of America (08).

Radiographic findings in children include narrow interpediculate space of the caudal spine, a notch-like sacroiliac-groove, and chevron-shaped epiphyseal ossification centers on the metaphysis (66; 32; 120).

A 2000 to 2019 study of 108 participant children with achondroplasia showed 52 (48%) participants presenting with craniocervical stenosis, 15 (13.9%) with hydrocephalus, 66 (61.1%) with hearing impairment, 44 (40.7%) with sleep-disordered breathing, 46 (42.6%) with lower-limb malalignment, 24 (22.2%) with thoracolumbar kyphosis, 10 (9.3%) with symptomatic spinal stenosis, 12 (11.1%) with obesity, and 16 (14.8%) who had at least one admission for respiratory illness (03).

Prognosis and complications

Over their lifespan, individuals with achondroplasia often have multisystem complications, reduced quality of life and functionality, and increased pain (03; 73). Most individuals with achondroplasia are of normal intelligence and are able to lead independent and productive lives (127). Unexpected death in the absence of aggressive acute evaluation occurs in about 2% to 5% of infants with achondroplasia (96; 100). Early or unexpected death typically results from respiratory insufficiency because of a small thoracic cage and neurologic deficit from cervicomedullary stenosis (32; 26).

Children up to 7 years of age with achondroplasia show delayed milestone acquisition and a greater need for caregiver assistance for all domains (53). Examination of development in patients with achondroplasia show that height, weight, or head circumference do not appear to influence timing of gross motor skills before 5 years (55). The exception was lie to sit transitioning, which appears likely to occur earlier if the child is taller and heavier at 12 months, and later if the child has significant head-to-body disproportion. As functional delays are likely to be related to common musculoskeletal impairments associated with achondroplasia, access to physiotherapists, occupational therapists, and speech and language pathologists skilled in achondroplasia management may assist children and families to become more independent, particularly around the time of starting school. Advances in genetics may enable personalized medicine interventions that promote independent functioning and participation for individuals with achondroplasia (83).

The adult males attain an average height of approximately 131 cm, and females, a height of 124 cm. The average adult male weighs 55 kg, and average female, 40 kg (48; 44). Individuals with achondroplasia have an increased overall and age-specific mortality (36; 143). Progressive kyphosis or lordosis may lead to symptomatic spinal stenosis requiring surgical decompression. Heart disease-related mortality between the ages of 25 and 35 years is 10 times higher than in the general population. Overall mortality in individuals with achondroplasia is decreased by about 10 years (36). Today, mortality in babies with achondroplasia may be decreasing when compared to historic studies (118). Recurrent acute life-threatening events have been associated with achondroplasia (05).

At Johns Hopkins Hospital an MRI study involving 16 children with achondroplasia and 16 matched controls suggests that in children with achondroplasia, the variation in ventricular dilatation may be related to an unquantifiable interdependent relationship of emissary vein enlargement, venous channel narrowing, and foramen magnum compression. Secondly, stable ventricular size facilitated by interdependent factors likely obviates the need for ventricular shunt placement (10). Another study involving diffusion tensor imaging (DTI) showed reduction in fractional anisotropy and increase in diffusivities in the lower brainstem of participants with achondroplasia, which may reflect secondary encephalomalacic degeneration and cavitation of the affected white matter tracts as shown by histology. In children with achondroplasia, DTI may serve as a potential biomarker for brainstem white matter injury and aid in the care and management of these patients (11). An investigational study was conducted to evaluate early postnatal FGFR3 therapy to prevent obesity in achondroplasia (104).

Biological basis

Etiology and pathogenesis

Achondroplasia is an autosomal dominant disorder caused by mutations in fibroblast growth factor receptor type 3 (FGFR3) (101; 114; 94). About 80% of patients are born to unaffected parents, representing a high rate of de novo mutations. In 1994, the achondroplasia locus was mapped to 4p16.3 (69; 133). Individuals with achondroplasia have one normal copy of FGFR3 and one mutant copy. Gene penetrance is 100%, meaning all individuals who have a single copy of altered FGFR3 have achondroplasia. Homozygosity for the mutation results in fatality before or shortly after birth (95). About 98% of cases are caused by point mutations that result in the amino acid substitution Gly380Arg, and about 1% of cases are caused by glycine and cysteine point mutation (114; 07; 102). A technique called quantitative imaging FRET showed a statistically significant increase in FGFR3 dimerization in the achondroplasia mutation compared to wild type HEK293T cells, suggesting a structural change in the plasma membrane that affects both the stability and activity of FGFR3 dimers in the absence of the ligand (99). Paternal allelic germline mosaicism has been noted in sperm, suggesting increased mutability of FGFR3 during spermatogenesis or a selective advantage for this pathogenic mutation in the male cell line (87). Advanced paternal age is associated with the mutation and disease severity (97; 122; 124). Evidence of positive selection helps to explain the paternal age effect in achondroplasia (116; 31).

Achondroplasia, hypochondroplasia, and thanatophoric dysplasia are syndromes of short-limbed dwarfism caused by activating mutations of fibroblast growth factor receptor-3, which result in over-activation of the MEK/ERK MAP kinase pathway. C-type natriuretic peptide (CNP) is a crucial regulator of endochondral bone growth. In these skeletal dysplasias, elevated plasma levels of proCNP products suggest the presence of tissue resistance to CNP (90).

Hypochondroplasia is an autosomal dominant skeletal dysplasia with milder features than those seen in achondroplasia. McKusick and colleagues noted that achondroplasia and hypochondroplasia possessed phenotypic similarities and proposed that these similarities are based on the same allele (80). Although this was found to be true, polymerase chain reaction, linkage studies, and restriction analysis of the FGFR3 gene show a tendency for N540K mutations to result in hypochondroplasia, whereas mutations at G1138A were found more frequently in achondroplasia (07; 74). De novo variants in the transmembrane domain of FGFR3 have been reported to cause achondroplasia (85).

The FGFR3 cDNA was originally isolated when scientists were searching for the Huntington disease gene on chromosome 4p16.3 (125). The FGFR3 gene codes for a protein involved in the negative regulation of bone growth. Therefore, mutations result in gain-of-function and abnormal growth control exerted by the FGFR3 pathway (20; 126). Two pathways involved in FGFR3 signaling, signal transducers and activators of transcription, and extracellular signal-related kinases inhibit chondrocyte proliferation and differentiation through mitogen-activated protein kinase signaling, thus, delaying endochondral ossification (103; 84; 71). Increased FGFR3 activity raises the probability of phosphorylation of unliganded mutant dimers (34). Thus, dysfunctional FGFR3 protein results in a gain-of-function enhancement of tyrosine kinase activity, disruption of chondrocyte proliferation and differentiation, and ultimately affects growth plate architecture (77).

Diagnostic workup

Features of achondroplasia are so distinctive that physical examination and radiographic features are often sufficient to make a diagnosis. Genetic testing for FGFR3 mutations is not routinely performed but may be confirmatory. Many patients are diagnosed by the third trimester of pregnancy by prenatal ultrasound demonstrating foreshortened limbs (< 3rd percentile), increased biparietal diameter (> 95th percentile), and a low nasal bridge (18; 81; 12; 16). Caution should be exercised when counseling a family about a suspected in utero diagnosis of achondroplasia because disproportionately short limbs are seen in a heterogenous group of disorders.

Fetal MRI is a useful diagnostic tool for skeletal dysplasias and excluded the diagnosis in nearly half of referred pregnancies (29). In addition to providing fetal lung volumes, fetal MRI demonstrates findings of the brain in achondroplasia and thanatophoric dysplasia, of the spine in achondroplasia and achondrogenesis, of the calvarium in osteogenesis imperfecta and thanatophoric dysplasia, and of the cartilage in Kniest dysplasia (29). Using MRI findings to predict cervical myelopathy and hydrocephalus may be useful for the management of achondroplasia. The cord constriction ratio for cervical myelopathy and frontal horn width and posterior indentation grade for hydrocephalus are significant predictors and may be useful parameters for management. Posterior indentation grade may also be used to determine the treatment method for hydrocephalus (115).

There have been few studies that study the correlation between second-trimester ultrasonographic findings and underlying molecular defect in cases of FGFR3-related skeletal dysplasias (33). Widening of the femoral diaphysis-metaphysis angle at 20 to 24 weeks may be a marker for the detection of achondroplasia prior to the onset of skeletal shortening (59). The combination of ultrasound and a molecular genetic approach may be helpful for establishing an accurate diagnosis of FGFR3-related skeletal dysplasias in utero and, subsequently, for appropriate genetic counseling and perinatal management. Gene testing for bone dysplasias using targeted next-generation sequencing shows promise for improving diagnostics of common skeletal dysplasias (148).

Growth charts for height, weight, head circumference, body mass index, and developmental milestones have been established for patients with achondroplasia (48; 130; 44; 46; 42; 45). Although features are distinctive at birth, short stature becomes gradually evident in childhood and through adulthood.

Management

Management of individuals with achondroplasia requires an understanding of the natural history of the disorder and a multidisciplinary approach because of the multiple medical problems that can arise. Hoover-Fong and colleagues offer a critical review and discussion of the natural history of achondroplasia based on evidence in the current literature and the perspectives of clinicians with extensive knowledge and practical experience in managing individuals with this diagnosis (43). Treatment for increasing growth in children with achondroplasia with the use of vosoritide, a modified analogue of c-type natriuretic peptide, has been approved (108; 105; 109).

There are numerous publications of guidelines for management of individuals with achondroplasia. For example, Australia has published guidelines on management of children with achondroplasia (129). Europe has published best practices on diagnosis and referral (19). Recommendations for the management and anticipatory guidance of individuals with achondroplasia were published by the American Academy of Pediatrics (130). A group of 55 international experts from 16 countries and five continents developed consensus statements and recommendations that aim to capture the key challenges and optimal management of achondroplasia across each major life stage and subspecialty area using a modified Delphi process (107). The primary purpose of this first International Consensus Statement is to facilitate the improvement and standardization of care for children and adults with achondroplasia worldwide to optimize their clinical outcomes and quality of life.

Recommendations for anticipatory guidance and management of individuals with achondroplasia

	(1) Monitor height, weight, and head circumference using growth curves standardized for achondroplasia.
	(2) Neurologic examinations (including consideration of tests such as CT, MRI, somatosensory evoked potentials, and polysomnography)
	(3) Surgical enlargement of the foramen magnum in cases of severe stenosis
	(4) Management of frequent middle ear infections and dental crowding. Repeated audiometry should be routinely performed during the first 3 years of life
	(5) Measures to control obesity starting in early childhood
	(6) Growth hormone therapy (experimental)
	(7) Limb-lengthening of the long bones
	(8) Tibial osteotomy of epiphysiodesis of the fibular growth plate to correct bowing of the legs
	(9) Lumbar laminectomy for symptomatic spinal stenosis
	(10) Genetic counseling for individuals and families to understand the cause of achondroplasia, the chance of having another child with achondroplasia, and to understand reproductive options
	(11) Pregnant women with achondroplasia can deliver by cesarean section.
	(12) Prenatal detection of fetuses with achondroplasia through ultrasound (eg, short femora < 24 weeks gestation)

This comprehensive policy statement may be helpful for clinicians directing ongoing care. Because adults with achondroplasia are at increased risk for spinal stenosis, a clinical history and neurologic examination is warranted every 3 to 5 years once the person with achondroplasia reaches mid-life (26). Quality-of-life indicators are helpful for assessing the need for support in both children and adults with achondroplasia (98; 147). The physician should consider in practice to monitor height, weight, and head circumference; discuss measures to avoid obesity; consider MRI or CT for evaluation of severe hypotonia or signs of spinal cord compression; adenotonsillectomy, continuous positive airway pressure by nasal mask, and tracheostomy to correct obstructive sleep apnea; suboccipital decompression as indicated for lower-limb hyperreflexia or clonus and central hypopnea; surgery to correct spinal stenosis; and educational support in socialization and school adjustment (26). A study of patients in Australia examined the use of services related to health management of achondroplasia (52). Growth charts and growth parameters for Australian children with achondroplasia have been published (128; 107). Recommendations for optimal management of complications were published as a result of these data (54). Access to geneticists and pediatricians within the first year is high as recommended by the 2005 American Academy of Pediatrics guidelines. Utilization of craniocervical magnetic resonance imaging/computed tomography, polysomnography studies, and formal speech review appears low, reflecting more emphasis on clinical monitoring for cervical cord compression and disordered sleep breathing as well as possible difficulties in accessing services for polysomnography and speech pathology. Over half of the children accessed physiotherapy or occupational therapy services, warranting consideration of these professionals in future guideline recommendations. Best practices in the evaluation and treatment of foramen magnum stenosis during infancy have been published (138).

Orthopedic surgery in the form of humeral and femoral lengthening in achondroplasia is an established technique. There are a variety of techniques and high complication rates (110). Controversy surrounding the risk of complications with cosmetic gains and quality of life persists (60; 61). With regard to thoracolumbar kyphosis, a study from Johns Hopkins Orthopaedics reported that kyphosis resolved at walking age in 15% of patients and after a year of walking in 58% of patients (75). The group suggests that earlier bracing may slow thoracolumbar kyphosis progression in patients with achondroplasia and developmental motor delay. Patients with kyphotic curves between 20 and 40 degrees should be examined intermittently for progressive deformity or worsening symptoms of spinal cord compression.

Data suggest a high population prevalence of hypertension among short-stature adults (41). Blood pressure should be monitored as part of routine medical care, and measuring at the forearm appears to be the only viable clinical option in rhizomelic short-stature adults with elbow contractures (41).

Trials investigating the efficacy of growth hormone therapy for increasing height in achondroplasia have long been reported, but most have been short-term studies (145; 58; 117; 136; 121; 113). Results showed an average increased growth velocity of 65% to 75% during the first year of treatment (15). One long-term study examined growth hormone treatment in children over 5 years (2 years of treatment followed by 1 year of observation, followed by 2 more years of treatment), and showed a 1.5 standard deviation increase in height without adverse effect on trunk-leg disproportion (39).

Therapeutic strategies have targeted reduction in FGFR3 signaling through tyrosine kinase inhibitors and neutralizing antibodies. Novel tyrosine kinase inhibitors such as A31 have been shown to inhibit FGFR3 phosphorylation and to restore the size of embryonic dwarf mice femurs in an ex vivo culture system (57). The increase in length of the treated mutant femurs was 2.6 times more than for the wild-type. A novel FGFR3 binding peptide, P3, inhibited tyrosine kinase activity of FGFR3 and its typical downstream molecules, extracellular signal-regulated kinase/mitogen-activated protein kinase, promoted proliferation and chondrogenic differentiation of cultured ATDC5 chondrogenic cells, alleviated the bone growth retardation in bone rudiments from mice mimicking human thanatophoric dysplasia type II (TDII), and reversed the neonatal lethality of TDII mice (56). These studies support the development of tyrosine kinase inhibitors for the treatment of FGFR3-related chondrodysplasias. Mutations in C-type natriuretic peptide present a novel cause for autosomal dominant short stature (40). Discoveries such as C-type natriuretic peptide administration counteracting signal transduction pathways downstream of FGFR3 in mice to ameliorate the clinical phenotype hold promise for therapeutic intervention (67; 146). A study observed an increase in the axial and appendicular skeleton lengths, and improvements in dwarfism-related clinical features included flattening of the skull, reduced crossbite, straightening of the tibias and femurs, and correction of the growth-plate defect in mice given BMN 111, a NEP-resistant C-type natriuretic peptide analog (72). A clinical trial in children with achondroplasia demonstrated that once-daily subcutaneous administration of vosoritide was associated with a side-effect profile that appeared generally mild (106). Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months.

Soluble FGFR-3 is being investigated as therapy for achondroplasia (02; 27). Clustered regularly interspaced short palindromic repeat (CRISPR) has arisen as a frontrunner for efficient genome engineering. Using this technology, Wojtal and colleagues demonstrated preferential elimination of the dominant-negative FGFR3 c.1138G>A allele in fibroblasts of an individual affected by achondroplasia (141).

Yamashita and colleagues showed that treatment of achondroplastic model mice with statin led to a significant recovery of bone growth (144). Statin treatment rescued patient-specific induced pluripotent stem cell (iPSC) models and a mouse model of FGFR3 skeletal dysplasia. These results suggest that statins could represent a medical treatment for infants and children with achondroplasia (91; 144).

Neurosurgical management of achondroplasia includes shunting for hydrocephalus and decompression surgery for spinal stenosis (62; 06). Cervicomedullary compression can cause pain, ataxia, incontinence, apnea, progressive quadriparesis, and respiratory arrest (30). The prevalence of cervicomedullary decompression among individuals with achondroplasia is about 20%, with more recently treated patients undergoing first cervicomedullary decompression at younger ages than earlier patients (68). The use of neuroimaging and polysomnogram screening modalities increased over time, suggesting that increased and better surveillance contributed to earlier identification and intervention in patients with cervicomedullary stenosis. Surgical relief of venous pressure is often used, but up to 10% of patients with hydrocephalus will require ventricular shunting (36; 30; 47). Clinical findings such as brisk tendon reflexes, small foramen magnum, and central hypopnea may be an indication for surgery, but the decision to operate can be difficult because cord compression may resolve spontaneously (30). Concerns arise when persistent kyphosis or lordosis progresses to spinal stenosis. Symptomatic stenosis is common in the third and fourth decades of life, and nearly one in three patients require lumbar laminectomy (120; 111; 112; 62). Surgical decompression with instrumentation significantly reduces the symptoms of lumbar stenosis and the likelihood of revision surgery in children with achondroplasia (06).

Although many children with achondroplasia have features of hydrocephalus with enlarged intracranial CSF spaces and relative macrocephaly, treatment of hydrocephalus in achondroplasia patients has become relatively uncommon in the last 20 years. Historically, there was a significant association between symptomatic foramen magnum stenosis and treatment of hydrocephalus, although concurrent treatment of both has fallen out of favor with the recognition that cervicomedullary decompression (CMD) alone will treat hydrocephalus in some patients. Despite good experimental data demonstrating that hydrocephalus in achondroplasia is best understood as communicating in nature, endoscopic third ventriculostomy (ETV) appears to be reasonably successful in certain patients and should be considered an option in selected patients (14).

Similarly, orthopedic surgery has been proposed for bone deformities in achondroplasia. Growth modulation is able to correct varus deformities of the legs in achondroplasia (79). In the CLARITY study, orthopedic surgery was a common occurrence in achondroplasia, with 29.7% of patients undergoing at least one orthopedic procedure (86). Spine surgery (12.7%) was less common and occurred at a later age than lower extremity surgery (21.2%). Cervicomedullary decompression and hydrocephalus with shunt placement were associated with an increased risk for spine surgery.

Although most individuals with achondroplasia have normal intelligence, the cognitive profile for individuals with achondroplasia may be unique. Neuropsychological evaluation and monitoring of children with achondroplasia suggest verbal IQ, arithmetic, attention, and executive functioning are particularly common areas of impairment (139).

Stigmas associated with short stature may affect individuals with achondroplasia and result in poor socialization. School adjustment may be a challenge for children. In addition to medical care, support in the form of groups (eg, Little People of America), peer support, programs to assist with employment and disability rights, camps, newsletters, and seminars may be instrumental in helping individuals reach their full potential and integrate into society.

References

01: Allanson JE, Hall JG. Obstetrics and gynecologic problems in women with chondrodystrophies. Obstet Gynecol 1986;67(1):74-8. PMID 3940342
02: Anonymous. Bone: Soluble FGFR-3 as potential therapy for achondroplasia. Nature Reviews Endocrinol 2013;9(12):692.
03: Armstrong JA, Pacey V, Tofts LJ. Medical complications in children with achondroplasia. Dev Med Child Neurol 2022;64(8):989-97. PMID 35238031
04: Awad AW, Aleck KA, Bhardwaj RD. Concomitant achondroplasia and Chiari II malformation: a double-hit at the cervicomedullary junction. World J Clin Cases 2014;2(11):711-6. PMID 25405196
05: Babiker MO, Edwards C, Davies P, O'Kane R. Recurrent acute life-threatening events in a child with achondroplasia. Arch Dis Child Educ Pract Ed 2015;100(1):19. PMID 25368135
06: Baca KE, Abdullah MA, Ting BL, et al. Surgical decompression for lumbar stenosis in pediatric achondroplasia. J Pediatr Orthop 2010;30(5):449-54. PMID 20574261
07: Bellus GA, McIntosh I, Smith EA, et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995;10(3):357-9. PMID 7670477
08: Bober M, Johnson C, Nicholson L, Scott C Jr. Scott sign: a clinical measure of ligamentous laxity in achondroplastic infants. Am J Med Genet 2008;146A(17):2291-2. PMID 18666221
09: Bodensteiner JB. Neurological manifestations of achondroplasia. Curr Neurol Neurosci Rep 2019;19(12):105. PMID 31782047
10: Bosemani T, Orman G, Carson KA, Meoded A, Huisman TA, Poretti A. Diffusion tensor imaging of the brainstem in children with achondroplasia. Dev Med Child Neurol 2014;56(11):1085-92. PMID 24825324
11: Bosemani T, Orman G, Hergan B, Carson KA, Huisman TA, Poretti A. Achondroplasia in children: correlation of ventriculomegaly, size of foramen magnum and jugular foramina, and emissary vein enlargement. Childs Nerv Syst 2015;31(1):129-33. PMID 25249421
12: Boulet S, Althuser M, Nugues F, Schaal JP, Jouk PS. Prenatal diagnosis of achondroplasia: new specific signs. Prenat Diagn 2009;29(7):697-702. PMID 19399756
13: Bruhl K, Stoeter P, Wietek B, et al. Cerebral spinal fluid flow, venous drainage and spinal cord compression in achondroplastic children: impact of magnetic resonance findings for decompressive surgery at the cranio-cervical junction. Eur J Pediatr 2001;160(1):10-20. PMID 11195012
14: Campbell J, Legare JM, Piatt J, et al. Achondroplasia Natural History Study (CLARITY): 60-year experience with hydrocephalus in achondroplasia from four skeletal dysplasia centers. J Neurosurg Pediatr 2023;32(6):649-56. PMID 37877951
15: Carter EM, Davis JG, Raggio CL. Advances in understanding etiology of achondroplasia and review of management. Curr Opin Pediatr 2007;19(1):32-7. PMID 17224659
16: Chitty LS, Griffin DR, Meaney C, et al. New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. Ultrasound Obstet Gynecol 2011;37(3):283-9. PMID 21105021
17: Coi A, Santoro M, Garne E, et al. Epidemiology of achondroplasia: a population-based study in Europe. Am J Med Genet A 2019;179(9):1791-8. PMID 31294928
18: Cordone M, Lituania M, Bocchino G, Passamonti U, Toma P, Camera G. Ultrasonographic features in a case of heterozygous achondroplasia at 25 weeks' gestation. Prenat Diagn 1993;13(5):395-401. PMID 8341638
19: Cormier-Daire V, AlSayed M, Alves I, et al. Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations. Orphanet J Rare Dis 2022;17(1):293. PMID 35897040
20: Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996;84(6):911-21. PMID 8601314
21: Dumitrascu CI, Eneh PN, Keim AA, Kraus MB, Sharpe EE. Anesthetic management of parturients with achondroplasia: a case series. Proc (Bayl Univ Med Cent) 2023;37(1):63-8. PMID 38173994
22: Ednick M, Tinkle BT, Phromchairak J, Egelhoff J, Amin R, Simakajornboon N. Sleep-related respiratory abnormalities and arousal pattern in achondroplasia during early infancy. J Pediatr 2009;155(4):510-5. PMID 19608200
23: Emerson CP. Achondroplasia. In: Modern Medicine: its theory and practice. Osler W, McCrae T, editors. Philadelphia: Lea & Febiger, 1909:683-703.
24: Emery WB. Great tombs of the first dynasty; excavations at Saqqara. Cairo: Government Press, 1954:36.
25: Filer J. Disease, Egyptian bookshelf. London: The British Museum Press, 1995:36-9.
26: Francomano CA. Achondroplasia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet] 2006. Seattle (WA): University of Washington, Seattle.
27: Garcia S, Dirat B, Tognacci T, et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci Transl Med 2013;5(203):203ra124. PMID 24048522
28: Ghalioungui P, El Dawakhly Z. Health and healing in ancient Egypt. Al-Maaref, Cairo: Egyptian Organization for Authorship and Translation, 1965:19-20.
29: Gilligan LA, Calvo-Garcia MA, Weaver KN, Kline-Fath BM. Fetal magnetic resonance imaging of skeletal dysplasias. Pediatr Radiol 2020 Feb;50(2):224-233. PMID 31776601
30: Gordon N. The neurological complications of achondroplasia. Brain Dev 2000;22(1):3-7. PMID 10761826
31: Goriely A, McGrath JJ, Hultman CM, Wilkie AO, Malaspina D. "Selfish spermatogonial selection": a novel mechanism for the association between advanced paternal age and neurodevelopmental disorders. Am J Psychiatry 2013;170(6):599-608. PMID 23639989
32: Hall JG. The natural history of achondroplasia. Basic Life Sci 1988;48:3-9. PMID 3071358
33: Hatzaki A, Sifakis S, Apostolopoulou D, et al. FGFR3 related skeletal dysplasias diagnosed prenatally by ultrasonography and molecular analysis: presentation of 17 cases. Am J Med Genet A 2011;155A(10):2426-35. PMID 21910223
34: He L, Horton W, Hristova K. Physical basis behind achondroplasia, the most common form of human dwarfism. J Biol Chem 2010;285(39):30103-14. PMID 20624921
35: Hecht JT, Bodensteiner JB, Butler IJ. Neurologic manifestations of achondroplasia. Handb Clin Neurol 2014;119:551-63. PMID 24365319
36: Hecht JT, Francomano CA, Horton WA, Annegers JF. Mortality in achondroplasia. Am J Hum Genet 1987;41(3):454-64. PMID 3631079
37: Hecht JT, Thompson NM, Weir T, Patchell L, Horton WA. Cognitive and motor skills in achondroplastic infants: neurologic and respiratory correlates. Am J Med Genet 1991;41(2):208-11. PMID 1785636
38: Hefner JT, Warren MW. Possible achondroplastic dwarf skull from Montevideo, Uruguay. J Forensic Sci 2016;61(6):1671-7. PMID 27636382
39: Hertel NT, Eklof O, Ivarsson S, et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr 2005;94(10):1402-10. PMID 16299871
40: Hisado-Oliva A, Ruzafa-Martin A, Sentchordi L, et al. Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature. Genet Med 2018;20(1):91-7. PMID 28661490
41: Hoover-Fong J, Alade AY, Ain M, et al. Blood pressure in adults with short stature skeletal dysplasias. Am J Med Genet A 2020;182(1):150-61. PMID 31729121
42: Hoover-Fong JE, Alade AY, Hashmi SS, et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genet Med 2021b;23(8):1498-505. PMID 34006999
43: Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone 2021a;146:115872. PMID 33545406
44: Hoover-Fong JE, McGready J, Schulze KE, Barnes H, Scott CI. Weight for age charts for children with achondroplasia. Am J Med Genet 2007;143A(19):2227-35. PMID 17764078
45: Hoover-Fong JE, Schulze KJ, Alade AY, et al. Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study- a multi-center retrospective cohort study of achondroplasia in the US. Orphanet J Rare Dis 2021c;16(1):522. PMID 34949201
46: Hoover-Fong JE, Schulze KJ, McGready J, Barnes H, Scott CI. Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height. Am J Clin Nutr 2008;88(2):364-731. PMID 18689372
47: Horton WA, Hall JG, Hecht J. Achondroplasia. Lancet 2007;370(9582):162-72. PMID 17630040
48: Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG. Standard growth curves for achondroplasia. J Pediatr 1978;93(3):435-8. PMID 690757
49: Huang J, Babins N. Anesthesia for cesarean delivery in an achondroplastic dwarf: a case report. AANA J 2008;76(6):435-6. PMID 19090312
50: Hunter AG, Bankier A, Rogers JG, Sillence D, Scott CI Jr. Medical complications of achondroplasia: a multicentre patient review. J Med Genet 1998;35(9):705-12. PMID 9733026
51: Ireland PJ, Johnson S, Donaghey S, et al. Developmental milestones in infants and young Australian children with achondroplasia. J Dev Behav Pediatr 2010;31(1):41-7. PMID 20081435
52: Ireland PJ, Johnson S, Donaghey S, et al. Medical management of children with achondroplasia: Evaluation of an Australasian cohort aged 0-5 years. J Paediatr Child Health 2012;48(5):443-9. PMID 22112170
53: Ireland PJ, McGill J, Zankl A, et al. Functional performance in young Australian children with achondroplasia. Dev Med Child Neurol 2011;53(10):944-50. PMID 21838822
54: Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet 2014;7:117-25. PMID 25053890
55: Ireland PJ, Ware RS, Donaghey S, et al. The effect of height, weight and head circumference on gross motor development in achondroplasia. J Paediatr Child Health 2013;49(2):E122-7. PMID 23336715
56: Jin M, Yu Y, Qi H, et al. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mol Genet 2012;21(26):5443-55. PMID 23014564
57: Jonquoy A, Mugniery E, Benoist-Lasselin C, et al. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. Hum Mol Genet 2012;21(4):841-51. PMID 22072392
58: Key LL Jr, Gross AJ. Response to growth hormone in children with chondrodysplasia. J Pediatr 1996;128(5 Pt 2):S14-7. PMID 8627462
59: Khalil A, Chaoui R, Lebek H, et al. Widening of the femoral diaphysis-metaphysis angle at 20-24 weeks: a marker for the detection of achondroplasia prior to the onset of skeletal shortening. Am J Obstet Gynecol 2016;214(2):291-2. PMID 26450406
60: Kim SJ, Agashe MV, Song SH, Choi HJ, Lee H, Song HR. Comparison between upper and lower limb lengthening in patients with achondroplasia: a retrospective study. J Bone Joint Surg Br 2012a;94(1):128-33. PMID 22219260
61: Kim SJ, Balce GC, Agashe MV, Song SH, Song HR. Is bilateral lower limb lengthening appropriate for achondroplasia.: midterm analysis of the complications and quality of life. Clin Orthop Relat Res 2012b;470(2):616-21. PMID 21785895
62: King JA, Vachhrajani S, Drake JM, Rutka JT. Neurosurgical implications of achondroplasia. J Neurosurg Pediatr 2009;4(4):297-306. PMID 19795959
63: Kozma C. Dwarfs in ancient Egypt. Am J Med Genet 2006;140(4):303-11. PMID 16380966
64: Kozma C. Historical review II: Skeletal dysplasia in ancient Egypt. Am J Med Genet Part A 2008;146A:3104-12. PMID 19006207
65: Kozma C. Genetic Drift. The ancient Egyptian dwarfs of the Walters Art Museum. Am J Med Genet 2010;152A(10):2556-62. PMID 20799327
66: Langer LO Jr, Baumann PA, Gorlin RJ. Achondroplasia. Am J Roentgenol Radium Ther Nucl Med 1967;100(1):12-26. PMID 6023888
67: Lee CY, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009;49(6):668-73. PMID 19395584
68: Legare JM, Liu C, Pauli RM, et al. Achondroplasia Natural History Study (CLARITY): 60-year experience in cervicomedullary decompression in achondroplasia from four skeletal dysplasia centers. J Neurosurg Pediatr 2021;1-7. PMID 34087800
69: Le Merrer M, Rousseau F, Legeai-Mallet L, et al. A gene for achondroplasia-hypochondroplasia maps to chromosome 4p. Nat Genet 1994;6(3):318-21. PMID 8012398
70: Lemyre E, Azouz EM, Teebi AS, Glanc P, Chen MF. Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update. Can Assoc Radiol J 1999;50(3):185-97. PMID 10405653
71: L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304(2):417-31. PMID 15748888
72: Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 2012;91(6):1108-14. PMID 23200862
73: Maghnie M, Semler O, Guillen-Navarro E, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis 2023;18(1):56. PMID 36922864
74: Mancilla EE, Poggi H, Repetto G, García C, Foradori A, Cattani A. [Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia]. [Article in Spanish] Rev Med Chil 2003;131(12):1405-10. PMID 15022403
75: Margalit A, McKean G, Lawing C, Galey S, Ain MC. Walking out of the curve: thoracolumbar kyphosis in achondroplasia. J Pediatr Orthop 2018;38(10):491-7. PMID 27636912
76: Martinez-Frias ML, Cereijo A, Bermejo E, López M, Sánchez M, Gonzalo C. Epidemiological aspects of Mendelian syndromes in a Spanish population sample: I. Autosomal dominant malformation syndromes. Am J Med Genet 1991;38(4):622-5. PMID 2063907
77: Martinez-Frias ML, de Frutos CA, Bermejo E, Nieto MA; ECEMC Working Group. Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia. Am J Med Genet A 2010;152A(1):245-55. PMID 20034074
78: Mayhew JF, Katz J, Miner M, Leiman BC, Hall ID. Anaesthesia for the achondroplastic dwarf. Can Anaesth Soc J 1986;33(2):216-21. PMID 3697817
79: McClure PK, Kilinc E, Birch JG. Growth modulation in achondroplasia. J Pediatr Orthop 2017;37(6):e384-7. PMID 28719547
80: McKusick VA, Kelly TE, Dorst JP. Observations suggesting allelism of the hypochondroplasia and achondroplasia genes. J Med Genet 1973;10(1):11-6. PMID 4697848
81: Mesoraca A, Pilu G, Perolo A, et al. Ultrasound and molecular mid-trimester prenatal diagnosis of de novo achondroplasia. Prenat Diagn 1996;16(8):764-8. PMID 8878289
82: Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995;11(4):462-4. PMID 7493034
83: Msall ME. Personalized medicine and the importance of measuring functioning and participation over time: lessons from achondroplasia. Dev Med Child Neurol 2011;53(10):882-3. PMID 21838817
84: Murakami S, Kan M, McKeehan WL, de Crombrugghe B. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 2000;97(3):1113-18. PMID 10655493
85: Nagata T, Matsushita M, Mishima K, et al. Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: a case report. Mol Genet Genomic Med 2020;8(3):e1148. PMID 31975530
86: Nahm NJ, Mackenzie WGS, Mackenzie WG, et al. Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers. Orphanet J Rare Dis 2023;18(1):139. PMID 37280669
87: Natacci F, Baffico M, Cavallari U, et al. Germline mosaicism in achondroplasia detected in sperm DNA of the father of three affected sibs. Am J Med Genet A 2008;146A(6):784-6. PMID 18266238
88: Oberklaid F, Danks DM, Jensen F, Stace L, Rosshandler S. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J Med Genet 1979;16(2):140-6. PMID 458831
89: Okazaki T, Saito Y, Ueda R, et al. Epileptic phenotype of FGFR3-related bilateral medial temporal lobe dysgenesis. Brain Dev 2017;39(1):67-71. PMID 27485793
90: Olney RC, Prickett TC, Espiner EA, et al. C-type natriuretic peptide (CNP) plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. J Clin Endocrinol Metab 2015;100(2):E355-E359. PMID 25387261
91: Olsen BR. Disease models: statins give bone growth a boost. Nature 2014;513(7519):494-5. PMID 25231860
92: Orioli IM, Castilla EE, Barbosa-Neto JG. The birth prevalence rates for the skeletal dysplasias. J Med Genet 1986;23(4):328-32. PMID 3746832
93: Parrot J. Sur la malformation achondroplastique et le Diu Ptauh. Bull Soc Anthrop 1878;1(296).
94: Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis 2019;14(1):1. PMID 30606190
95: Pauli RM, Conroy MM, Langer LO Jr, et al. Homozygous achondroplasia with survival beyond infancy. Am J Med Genet 1983;16(4):459-73. PMID 6660245
96: Pauli RM, Scott CI, Wassman ER Jr, et al. Apnea and sudden expected deaths in infants with achondroplasia. J Pediatr 1984;104(3):342-8. PMID 6707788
97: Penrose LS. Parental age and mutation. Lancet 1955;269(6885):312-3. PMID 13243724
98: Pfeiffer KM, Brod M, Smith A, et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am J Med Genet A 2021;185(1):33-45. PMID 33084192
99: Placone J, Hristova K. Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET. PLoS One 2012;7(10):e46678. PMID 23056398
100: Reid CS, Pyeritz RE, Kopits SE, et al. Cervicomedullary compression in young patients with achondroplasia: value of comprehensive neurologic and respiratory evaluation. J Pediatr 1987;110(4):522-30. PMID 3559799
101: Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994;371(6494):252-4. PMID 8078586
102: Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm Res 1996;45(1-2):108-10. PMID 8742128
103: Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999;13(11):1361-6. PMID 10364154
104: Saint-Laurent C, Garcia S, Sarrazy V, et al. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia. PLoS One 2018;13(4):e0195876. PMID 29652901
105: Savarirayan R, Hoover-Fong J, Yap P, Fredwall SO. New treatments for children with achondroplasia. Lancet Child Adolesc Health 2024a;8(4):301-10. PMID 38485412
106: Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 2019;381(1):25-35. PMID 31269546
107: Savarirayan R, Irving M, Harmatz P, et al. Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study. Genet Med 2022;24(12):2444-52. PMID 36107167
108: Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 2020;396(10252):684-92. PMID 32891212
109: Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health 2024b;8(1):40-50. PMID 37984383
110: Schiedel F, Rodl R. Lower limb lengthening in patients with disproportionate short stature with achondroplasia: a systematic review of the last 20 years. Disabil Rehabil 2012;34(12):982-7. PMID 22112021
111: Schkrohowsky JG, Hoernschemeyer DG, Carson BS, Ain MC. Early presentation of spinal stenosis in achondroplasia. J Pediatr Orthop 2007;27(2):119-22. PMID 17314632
112: Sciubba DM, Noggle JC, Marupudi NI, et al. Spinal stenosis surgery in pediatric patients with achondroplasia. J Neurosurg 2007;106(5 Suppl):372-8. PMID 17566204
113: Seino Y, Yamanaka Y, Shinohara M, et al. Growth hormone therapy in achondroplasia. Horm Res 2000;53 Suppl 3:53-6. PMID 10971105
114: Shiang R, Thompsom LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994;78(2):335-42. PMID 7913883
115: Shim Y, Ko JM, Cho TJ, Kim SK, Phi JH. Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia. Orphanet J Rare Dis 2021;16(1):81. PMID 33579320
116: Shinde DN, Elmer DP, Calabrese P, Boulanger J, Arnheim N, Tiemann-Boege I. New evidence for positive selection helps explain the paternal age effect observed in achondroplasia. Hum Mol Genet 2013;22(20):4117-26. PMID 23740942
117: Shohat M, Tick D, Barakat S, Bu X, Melmed S, Rimoin DL. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 1996;81(11):4033-7. PMID 8923856
118: Simmons K, Hashmi SS, Scheuerle A, Canfield M, Hecht JT. Mortality in babies with achondroplasia: revisited. Birth Defects Res A Clin Mol Teratol 2014;100(4):247-9. PMID 24677650
119: Sisk EA, Heatley DG, Borowski BJ, Leverson GE, Pauli RM. Obstructive sleep apnea in children with achondroplasia: surgical and anesthetic considerations. Otolaryngol Head Neck Surg 1999;120(2):248-54. PMID 9949360
120: Spranger JW, Brill PW, Poznanski AK. Achondroplasia. In: Bone dysplasias: an atlas of genetic disorders of skeletal development. 2nd ed. New York: Oxford University Press, 2002:82-9.
121: Stamoyannou L, Karachaliou F, Neou P, Papataxiarchou K, Pistevos G, Bartsocas CS. Growth and growth hormone therapy in children with achondroplasia: a two-year experience. Am J Med Genet 1997;72(1):71-6. PMID 9295079
122: Stoll C, Roth MP, Bigel P. A reexamination on parental age effect on the occurrence of new mutations for achondroplasia. Prog Clin Biol Res 1982;104:419-26. PMID 6891789
123: Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A 2007;143(1):1-18. PMID 17120245
124: Thompson JN Jr, Schaefer GB, Conley MC, Mascie-Taylor CG. Achondroplasia and parental age. N Engl J Med 1986;314(8):521-2. PMID 3945286
125: Thompson LM, Plummer S, Schalling M, et al. A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics 1991;11(4):1133-42. PMID 1664411
126: Thompson LM, Raffioni S, Zhu YZ, et al. Biological studies of mutations in FGFR3 which cause skeletal dysplasias. Am J Hum Genet 1996;59:161.
127: Thompson NM, Hecht JT, Bohan TP, et al. Neuroanatomic and neurophysiologic outcome in school-age children with achondroplasia. Am J Med Genet 1999;88(2):145-53. PMID 10206234
128: Tofts L, Das S, Collins F, Burton KL. Growth charts for Australian children with achondroplasia. Am J Med Genet A 2017;173(8):2189-200. PMID 28599087
129: Tofts LJ, Armstrong JA, Broley S, et al. Australian guidelines for the management of children with achondroplasia. J Paediatr Child Health 2023;59(2):229-41. PMID 36628540
130: Trotter TL, Hall JG; American Academy of Pediatrics Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics 2005;116(3):771-83. PMID 16140722
131: Vajo Z, Fancomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000;21(1):23-39. PMID 10696568
132: Van Hecke D, De Ville A, Van der Linden P, Faraoni D. Anaesthesia and orphan disease: a 26-year-old patient with achondroplasia. Eur J Anaesthesiol 2013;30(12):776-9. PMID 24161935
133: Velinov M, Slaugenhaupt SA, Stoilov I, Scott CI Jr, Gusella JF, Tsipouras P. The gene for achondroplasia maps to the telomeric region of chromosome 4p. Nat Genet 1994;6(3):314-7. PMID 8012397
134: Walts LF, Finerman G, Wyatt GM. Anesthesia for dwarfs and other patients of pathological small stature. Can Anaesth Soc J 1975;22(6):703-9. PMID 1201473
135: Wardall GJ, Frame WT. Extradural anaesthesia for cesarean section in achondroplasia. Br J Anaesth 1990;64(3):367-70. PMID 2328185
136: Weber G, Prinster C, Meneghel M, et al. Human growth hormone treatment in prepubertal children with achondroplasia. Am J Med Genet 1996;61(4):396-400. PMID 8834055
137: Weeks KR. The anatomical knowledge of the ancient Egyptians and the representation of the figure in Egyptian art. PhD Thesis, Yale University, 1970.
138: White KK, Bompadre V, Goldberg MJ, et al. Best practices in the evaluation and treatment of foramen magnum stenosis in achondroplasia during infancy. Am J Med Genet A 2016;170(1):42-51. PMID 26394886
139: Wigg K, Tofts L, Benson S, Porter M. The neuropsychological function of children with achondroplasia. Am J Med Genet A 2016;170(11):2882-8. PMID 27605460
140: Wight JM, Male D, Combeer A. Ultrasound-guided combined spinal-epidural anaesthesia for elective caesarean section in a patient with achondroplasia. Int J Obstet Anesth 2013;22(2):168-9. PMID 23473550
141: Wojtal D, Kemaladewi DU, Malam Z, et al. Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. Am J Hum Genet 2016;98(1):90-101. PMID 26686765
142: Woo EJ, Lee WJ, Hu KS, Hwang JJ. Paleopathological study of dwarfism-related skeletal dysplasia in a late Joseon Dynasty (South Korean) population. PLoS One 2015;10(10):e0140901. PMID 26488291
143: Wynn J, King TM, Gambello MJ, Waller DK, Hecht JT. Mortality in achondroplasia study: a 42-year follow-up. Am J Med Genet A 2007;143A(21):2502-11. PMID 17879967
144: Yamashita A, Morioka M, Kishi H, et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 2014;513(7519):507-11. PMID 25231866
145: Yamate T, Kanzaki S, Tanaka H, et al. Growth hormone (GH) treatment in achondroplasia. J Pediatr Endocrinol 1993;6(1):45-52. PMID 8374688
146: Yasoda A, Kitamura H, Fujii T, et al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 2009;150(7):3138-44. PMID 19282381
147: Yonko EA, Emanuel JS, Carter EM, Raggio CL. Quality of life in adults with achondroplasia in the United States. Am J Med Genet A 2021;185(3):695-701. PMID 33369042
148: Zhang H, Yang R, Wang Y, et al. A pilot study of gene testing of genetic bone dysplasia using targeted next-generation sequencing. J Hum Genet 2015;60(12):769-76. PMID 26377240

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Ryan W Y Lee MD

Dr. Lee of the John A Burns School of Medicine at the University of Hawaii has no relevant financial relationships to disclose.
See Profile

Editor

Ann Tilton MD

Dr. Tilton has received honorariums from Allergan and Ipsen as an educator, advisor, and consultant.
See Profile

Former Authors

Michael V Johnston MD†

Patient Profile

Age range of presentation: 0 to 1 month, often prenatally
Sex preponderance: male=female
Heredity: autosomal dominant
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: None

ICD & OMIM codes

ICD-10: Achondroplasia: Q77.4
ICD-11: Achondroplasia: LD24.00
OMIM: Achondroplasia: #100800

Hypochondroplasia: #146000

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Achondroplasia

Associated Disorders

Spinal stenosis
Lumbar lordosis
Kyphoscoliosis
Hydrocephalus

Differential Diagnosis

severe hypochondroplasia
cartilage-hair hypoplasia (metaphysical chondrodysplasia, McKusick type)
pseudoachondroplasia
hypochondroplasia
severe achondroplasia with developmental delay
- acanthosis nigricans (SADDAN), thanatophoric dysplasia
- Muenke coronal craniosynostosis
- Crouzon syndrome with acanthosis nigricans

Also Relevant

Central sleep apnea
Megalencephaly
Obstructive sleep apnea
X-linked hydrocephalus

Clinical Categories

Web References

Guidelines

Anesthesiological Management of Patients with Achondroplasia

Achondroplasia

Achondroplasia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Recommendations for anticipatory guidance and management of individuals with achondroplasia

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

X-linked hydrocephalus (L1 syndrome)

Breath-holding spells

Cerebro-oculo-facio-skeletal syndrome

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Achondroplasia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Recommendations for anticipatory guidance and management of individuals with achondroplasia

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

X-linked hydrocephalus (L1 syndrome)

Breath-holding spells

Cerebro-oculo-facio-skeletal syndrome

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

This is an article preview.
Start a Free Account
to access the full version.